WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocess technology leadership, today announced that it has entered into a strategic partnership and a exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocess market.
Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo®, as well as the development of future products and technologies in partnership with DRS Daylight Solutions (“Daylight”). Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen chromatography and filtration systems to expand the presence of companies in the fast growing Process Analytics Technology (PAT) segment of the bioprocess market.
Daylight’s patented QCL-IR technology measures higher-order protein and nucleic acid structure, facilitating the measurement of protein aggregation, nucleic acid concentration and content, and other critical attributes in biological manufacturing process. Accurate readings are available in seconds, enabling real-time process monitoring in upstream and downstream manufacturing.
San Diego-based Daylight specializes in developing and manufacturing innovative solutions based on its QCL technology platform, which operates across the mid-IR spectral range. Daylight, known for its cutting-edge products supporting commercial, research, aerospace and defense markets, entered the bioprocess market in 2018 with its revolutionary Culpeo® instrument.
Tony J. Hunt, CEO of Repligen, said, “We are delighted to have signed this agreement with DRS Daylight Solutions, which complements our existing analytics portfolio from C Technologies, a pioneer of on-line, time-based process monitoring solutions. real. We believe the Daylight portfolio will serve to accelerate and expand the adoption of online process monitoring in the bioprocess industry. We look forward to working with Tim Day and the team at Daylight.
Dr. Timothy Day, Senior Vice President and General Manager of DRS Daylight Solutions, said, “We are thrilled to partner with Repligen to make QCL-IR-based solutions a game-changing technology in PAT. We believe Repligen is the best partner to achieve this, given their success with C Technologies and their track record in bioprocess innovation. We look forward to working with Tony Hunt and the Repligen team to provide bioprocessing customers with this breakthrough technology for measuring critical process parameters in the manufacturing of biologics. With real-time and highly reliable results, Culpeo® will ultimately improve production yields, reduce costs and ensure product quality.
About DRS Daylight Solutions
DRS Daylight Solutions, a business unit of Leonardo DRS, is a leading provider of premier mid-infrared lasers and systems for the defense, commercial and research markets. Our global leadership position in advanced mid-infrared technology means our customers enjoy a sustainable competitive advantage in molecular sensing and imaging applications.
Leonardo DRS is headquartered in Arlington, Virginia, and is a leading supplier of mid-tier defense products and technologies to the U.S. military and its allies, with core capabilities in the areas of detection technology, force protection, networked computing, electrical power and propulsion. For more information about Daylight, please visit our website at https://daylightsolutions.com.
About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the manufacturing process of biologic drugs. We inspire advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are filtration, chromatography, process analysis, fluid management and proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey, and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and in Sweden. For additional company information, including Repligen press releases, see our website at http://www.repligen.com. Follow us on LinkedIn and Twitter.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as than amended. Investors are cautioned that statements contained in this press release that are not strictly historical, including, without limitation, express or implied statements regarding QCL-IR-based product development, technology performance and the expected synergies from Repligen’s partnership with Daylight constitute – forward-looking statements identified by words such as “believe”, “expect”, “may”, “will”, “should”, “seek”, “anticipate” or “could” and similar expressions. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully develop our bioprocesses business, particularly following an acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisition, our ability to develop and commercialize products and market acceptance of our products; reduced demand for our products which negatively impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger and better-funded bioprocess, pharmaceutical and biotechnology companies; our compliance with all Food and Drug Administration and EMEA regulations; the volatility of our stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission and other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those of Repligen contemplated by such forward-looking statements. These forward-looking statements reflect the current views of management, and Repligen does not undertake to update these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof, except as required by law. requires it.
Global Head of Investor Relations
Vice President, Communications